MIORG

RESISTANCE
CAN BE
BROKEN

MIORG is a Finnish preclinical immuno-oncology company developing therapeutic programs for cancers that resist current immunotherapies.

MIORG at a glance

From patient biology to preclinical programs built for partnership.

We start with patient-derived tumor biology to identify why cancer immunotherapies succeed or fail. We then translate those insights into focused, biomarker-informed therapeutic programs for pharmaceutical partnering.

How we work

A disciplined route from clinical insight to therapeutic opportunity.

Our approach combines clinical relevance, functional immunology, and computational design to create programs with a clear biological rationale.

01

Start with patients

Patient-derived samples, multiomic profiling, and AI-guided systems immunology reveal clinically grounded resistance mechanisms.

02

Validate the biology

Functional assays and preclinical models determine which mechanisms can become meaningful therapeutic opportunities.

03

Design the asset

Computational immunochemistry and therapeutic design turn validated biology into focused preclinical programs.

Why MIORG

An asset engine built around an urgent unmet need.

Cancer immunotherapy has transformed oncology, but many tumors remain resistant. MIORG is built to address this gap with patient-grounded discovery and partnership-ready preclinical development.

01

Clinically grounded

Programs begin with patient-derived biology, keeping the discovery process tied to real disease mechanisms.

02

Built to be de-risked

Functional validation, biomarker rationale, and therapeutic design create a clearer path from insight to asset.

03

Built to partner

MIORG develops focused preclinical programs intended for licensing, co-development, and pharmaceutical partnerships.

Pipeline

A focused therapeutic and diagnostic portfolio.

Lead therapeutic program

MIO-36 is a monoclonal antibody program designed to engage innate immune activity in resistant tumor settings and help drive adaptive antitumor T-cell responses, creating a stronger biological foundation for rational immunotherapy combinations.

Asset-generation platform

MIORG is building antibody and peptide programs around validated immune-resistance biology, biomarker-guided patient selection, and rational treatment combinations.

Founder-led science

Founder-led translational immunology.

MIORG is led by Carlos Rogério Figueiredo, PhD, a cancer immunologist and translational scientist focused on discovering and targeting immune resistance mechanisms that limit the effectiveness of cancer immunotherapy.

The company is being built around reverse translational precision oncology, connecting patient-derived biology to therapeutic antibody and peptide assets intended for preclinical proof-of-concept and pharmaceutical partnering.